Clinical Trial Update: A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I [NA]

View source ↗

Summary

Clinical trial assessing intrathecal enzyme therapy for cognitive decline in mucopolysaccharidosis type I has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hurler Syndrome
• Mucopolysaccharidosis
• Scheie Syndrome

Snippet

Sponsor: Patricia I. Dickson, M.D. | Conditions: Cognitive Decline, Mucopolysaccharidosis I | NA | Status: COMPLETED